U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung
Go back to U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung| (NASDAQ: LQDA) | Delayed: 66.88 -1.51 (2.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.39 | 52 Week High | $ | |||
| Open | $68.08 | 52 Week Low | $ | |||
| Day High | $68.72 | P/E | N/A | |||
| Day Low | $66.57 | EPS | $ | |||
| Volume | 3,896,375 | |||||
